EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Current and Future Landscape of Hepatocellular Carcinoma Treatment

Shadi Zerehpoosh, Yasuhito Tanaka, Said A Al-Busafi, Gulnara Aghayeva, Samir Rouabhia, Qiuwei Pan, Mohammed Eslam

Oncology Research · 2026

DOI: 10.32604/or.2026.076937 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology Research, 2026. Verfasst von Shadi Zerehpoosh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) represents a critical global health challenge, standing as a leading cause of cancer mortality with a significant and projected increasing incidence worldwide. A primary hurdle in HCC management is late diagnosis, often attributable to the absence of early symptoms. Despite considerable advancements in therapeutic strategies over the past decade, including immune checkpoint inhibitors and targeted therapies, mortality rates remain high, underscoring the urgent need for more effective novel approaches. The inherent molecular complexity and heterogeneity of HCC, where only a minority of tumors possess readily targetable drivers, contribute to treatment resistance and recurrence, even after curative interventions. Addressing these challenges, combination therapies, integrating immunotherapy with targeted agents, are emerging as a promising strategy to enhance efficacy and overcome resistance. This review comprehensively explores the current landscape of HCC treatment and the advancements in systemic therapies, including molecularly targeted agents and immunotherapies, and highlights ongoing challenges and future directions in this rapidly evolving field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansImmunotherapyMolecular Targeted TherapyCombined Modality TherapyImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

Hepatocellular carcinoma (HCC)combination therapyimmunotherapysystemic therapytargeted therapy

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, NSW, Australia.
  • Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, Japan.
  • Department of Medicine, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.
  • Medical Research Center, Sultan Qaboos University, Muscat, Oman.
  • Liver Diseases Department, Baku Health Center, Baku, Azerbaijan.
  • Department of Internal Medicine, University Hospital Center Touhami Benflis, Batna, Algeria.

Zitieren

APA

Zerehpoosh, S., Tanaka, Y., Al-Busafi, S. A., Aghayeva, G., Rouabhia, S., Pan, Q., & Eslam, M. (2026). Current and Future Landscape of Hepatocellular Carcinoma Treatment. Oncology Research. https://doi.org/10.32604/or.2026.076937

Vancouver

Zerehpoosh S, Tanaka Y, Al-Busafi SA, Aghayeva G, Rouabhia S, Pan Q, et al. Current and Future Landscape of Hepatocellular Carcinoma Treatment. Oncology Research. 2026. doi:10.32604/or.2026.076937

BibTeX
@article{Zerehpoosh2026,
  author = {Zerehpoosh, Shadi and Tanaka, Yasuhito and Al-Busafi, Said A and Aghayeva, Gulnara and Rouabhia, Samir and Pan, Qiuwei and Eslam, Mohammed},
  title = {Current and Future Landscape of Hepatocellular Carcinoma Treatment},
  journal = {Oncology Research},
  year = {2026},
  doi = {10.32604/or.2026.076937}
}
Kostenlos starten →